BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.